Please assess the completion status of the following clinical trial:

Trial Title: Study of Enbrel (Etanercept) for the Treatment Sub-Acute Pulmonary Dysfunction After Allogeneic Stem Cell Transplant

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Recipients of allogeneic bone marrow, cord blood, or peripheral blood stem cell transplants are eligible~* Age \>6 years and able to complete pulmonary function testing~* Patients with evidence of sub-acute, non-infectious pulmonary dysfunction (OLD or RLD)~* Recipients of sub-ablative transplant regimens are eligible~* Recipients of donor leukocyte infusions (DLI) post-transplant are eligible~* Patients must be \> 100 days post transplant~Exclusion Criteria:~* Patients with hypotension requiring inotropic agents other than dopamine \< 5mcg/ kg/ minute for blood pressure support.~* Patients with a positive quantitative bacterial culture from the BAL fluid (≥ 104 CFU/ ml is considered positive)~* Patients whose BAL fluid is positive for significant bacterial pathogens or pathogenic nonbacterial microorganisms (as defined by protocol) by special stain, culture or PCR analysis~* Patients who are enrolled on a phase I or phase II trial for the prophylaxis or treatment of GVHD (acute or chronic) within 7 days of study entry.~* Patients with known hypersensitivity to etanercept.~* Patients who are pregnant.~* Patients with CMV seropositivity at the time of study entry. Testing may include wither CMV PCR analysis or CMV pp65 testing.~* Evidence for multi-system organ failure.

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- etanercept treatment (Type: EXPERIMENTAL): Etanercept for lung injury

Based on this trial design, predict the completion outcome and termination type (if applicable).